9 patents currently held
54 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Nov 2031. from the record
Of the 54 now held by other companies, 48 name Altera Corporation as their current owner, and 6 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Nov 2031
Next term end
5
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2038 · High confidence
Also notable
Ends May 2037 · High confidence
Also notable
Ends Oct 2035 · High confidence
Population-Based Medication Risk Stratification and Personalized Medication Risk Score
US 11,361,856
A family of 5 related applications built on the 2022 grant. Protection runs to 2038.
Treatment Methods Having Reduced Drug-Related Toxicity and Methods of Identifying the Likelihood of Patient Harm from Prescribed Medications
US 10,890,577
A family of 5 related applications built on the 2021 grant. Protection runs to 2037.
Medication Risk Mitigation System and Method
US 10,720,241
The earliest of the three still in force, granted 2020 and renewed since. Its term ends first, in 2035.
Formerly held, still cited
Notable
Ends Dec 2028 · High confidence
Cited by 63 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
now held by Tahoe Research, Ltd.
Also notable
Ends May 2034 · High confidence
The most cited patent in this portfolio, cited by 70 later US patents, top 10% of utility patents granted in 2015 in our data. Protection runs to 2034.
now held by Altera Corporation
Also notable
Ends Jan 2027 · Medium confidence
Cited by 37 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
now held by Altera Corporation
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 7, 2027The maintenance fee for Treatment Methods Having Reduced Drug-Related Toxicity and Methods of Identifying the Likelihood of Patient Harm from Prescribed Medications (US 11,808,759) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Medication Risk Mitigation System and Method (US 11,862,343) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
What they patent
The 3 largest of its 5 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,392,220 | Medication Management System and Method In force · High confidence | In force | High confidence | |
| US 10,720,241 | Medication Risk Mitigation System and Method In force · High confidence | In force | High confidence | |
| US 11,862,343 | Medication Risk Mitigation System and Method In force · High confidence | In force | High confidence | |
| US 10,890,577 | Treatment Methods Having Reduced Drug-Related Toxicity and Methods of Identifying the Likelihood of Patient Harm from Prescribed Medications held by Tabula Rasa Healthcare, Inc. In force · High confidence | In force | High confidence | |
| US 11,808,759 | Treatment Methods Having Reduced Drug-Related Toxicity and Methods of Identifying the Likelihood of Patient Harm from Prescribed Medications held by Tabula Rasa Healthcare, Inc. In force · High confidence | In force | High confidence | |
| US 12,474,326 | Treatment Methods Having Reduced Drug-Related Toxicity and Methods of Identifying the Likelihood of Patient Harm from Prescribed Medications held by Tabula Rasa Healthcare, Inc. In force · High confidence | In force | High confidence | |
| US 11,361,856 | Population-Based Medication Risk Stratification and Personalized Medication Risk Score held by Tabula Rasa Healthcare, Inc. In force · High confidence | In force | High confidence | |
| US 12,159,723 | Population-Based Medication Risk Stratification and Personalized Medication Risk Score held by Tabula Rasa Healthcare, Inc. In force · High confidence | In force | High confidence | |
| US D1,066,362 | Display Screen with Graphical User Interface held by Tabula Rasa Healthcare, Inc. In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 54 patents in force now held by others · 169 patents ended · 3 applications pending · 12 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.